Fighting against harmful trade agreements

Global Action Against Pharma Greed

We are not fooled: Global health activists confront pharmaceutical industry over excessive medicine prices On 1st April 2016, activists across…

Don’t Trade Away Our Health

DON’T TRADE AWAY OUR HEALTH – PHARMA ATTEMPTS TO UNDERMINE SOUTH AFRICAN PATENT LAW REFORM & ACCESS TO AFFORDABLE MEDICINES…

Hands off the Market Inquiry into Private Health Care!

27 May 2014: Last week the Treatment Action Campaign’s (TAC) partner SECTION27 closely monitored the court hearing of the case…

TAC Analysis of Political Party Responses to the People’s Health Manifesto

The Treatment Action Campaign (TAC) thanks the 10 political parties who responded to the 11 questions in our People’s Health…

MSF-SA, TAC, SECTION27 and He-Tic picket at the Consulate General of India

Members of MSF-SA, TAC, Section 27 and He-Tic will picket at the Consulate General of India this Wednesday, 8th February…

Open letter to the High Commissioner to India for South Africa from TAC and SECTION27

The Treatment Action Campaign and SECTION27 have written a letter to the High Commissioner for India in South Africa requesting…

We need the Patent Pool to work

A Joint Statement by Treatment Action Campaign, Treatment Action Group, HIV i-Base, European AIDS Treatment Group and SECTION27 17 November…

Say no to Novartis!

6 September 2011 The Treatment Action Campaign (TAC) supports the Union of India, Cancer Patients Aid Association & others in…

Proposed Economic Partnership agreement with the EU raises concerns about access to medicines

After stalling for some time, negotiations for an economic partnership agreement (EPA) between the European Union (EU) on the one…

TAC, SECTION27 and MSF South Africa call on the EU and India to stop the threats to people’s lives

The Treatment Action Campaign (TAC), SECTION27 and Médecins Sans Frontières / Doctors Without Borders (MSF) South Africa voice support for…

Letter to the High Commissioner for India to South Africa

During the 1990s and early 2000s generic competition drove down the prices of ARVs. Without these massive price reductions, nearly…

Competition Commission places condition on GSK and Aspen merger – GSK must license abacavir to generic manufacturers

GlaxoSmithKline (GSK), one of the world’s largest pharmaceutical developers, and Aspen Pharmacare, South Africa’s largest generic pharmaceutical manufacturer, intend to…